AbbVie and Sandoz have resolved their patent dispute over AbbVie’s blockbuster immunology drug Rinvoq.
Sandoz admitted the Rinvoq patents asserted against it are “enforceable, valid, and would be infringed” by its proposed generic extended-release tablets ...
↧